Evotec Announces Change in Management Board
Evotec SE announced that Chief Operating Officer Dr Craig Johnstone will step down and leave the company effective December 31, 2024. Johnstone joined Evotec in 2012, serving various leadership roles before becoming COO in 2019. During his 12-year tenure, he played a key role in shaping Evotec and Global Operations. The COO responsibilities will be distributed internally across the Global Operations Leadership Team until a new organizational structure is announced following the Strategic Review.
Evotec SE ha annunciato che il Direttore Operativo Dr Craig Johnstone si dimetterà e lascerà l'azienda con effetto dal 31 dicembre 2024. Johnstone è entrato in Evotec nel 2012, ricoprendo vari ruoli di leadership prima di diventare COO nel 2019. Durante il suo mandato di 12 anni, ha svolto un ruolo chiave nel plasmare Evotec e le Operazioni Globali. Le responsabilità di COO saranno distribuite internamente tra i membri del Global Operations Leadership Team fino a quando non verrà annunciata una nuova struttura organizzativa a seguito della Revisione Strategica.
Evotec SE anunció que el Director de Operaciones Dr Craig Johnstone renunciará y dejará la empresa a partir del 31 de diciembre de 2024. Johnstone se unió a Evotec en 2012, ocupando varios roles de liderazgo antes de convertirse en COO en 2019. Durante su mandato de 12 años, desempeñó un papel clave en la configuración de Evotec y las Operaciones Globales. Las responsabilidades de COO se distribuirán internamente entre el equipo de liderazgo de operaciones globales hasta que se anuncie una nueva estructura organizativa tras la Revisión Estratégica.
Evotec SE는 최고 운영 책임자 Dr Craig Johnstone가 2024년 12월 31일부로 회사를 떠날 것이라고 발표했습니다. Johnstone은 2012년에 Evotec에 입사하여 다양한 리더십 역할을 수행한 후 2019년에 COO로 임명되었습니다. 12년 동안의 재임 기간 동안 그는 Evotec과 글로벌 운영에 중요한 역할을 했습니다. COO의 책임은 새로운 조직 구조가 전략적 검토 후 발표될 때까지 글로벌 운영 리더십 팀 내부에서 분배될 것입니다.
Evotec SE a annoncé que le Directeur des Opérations Dr Craig Johnstone démissionnera et quittera l'entreprise à compter du 31 décembre 2024. Johnstone a rejoint Evotec en 2012, occupant divers postes de direction avant de devenir COO en 2019. Au cours de ses 12 années en poste, il a joué un rôle clé dans la structuration d'Evotec et des Opérations Globales. Les responsabilités du COO seront réparties en interne au sein de l'équipe de leadership des opérations mondiales jusqu'à ce qu'une nouvelle structure organisationnelle soit annoncée à la suite de l'examen stratégique.
Evotec SE gab bekannt, dass der Chief Operating Officer Dr. Craig Johnstone zum 31. Dezember 2024 zurücktritt und das Unternehmen verlässt. Johnstone trat 2012 in Evotec ein, wo er verschiedene Führungspositionen innehatte, bevor er 2019 COO wurde. Während seiner 12-jährigen Amtszeit spielte er eine Schlüsselrolle bei der Gestaltung von Evotec und den globalen Operationen. Die Verantwortlichkeiten des COO werden bis zur Bekanntgabe einer neuen Organisationsstruktur nach der strategischen Überprüfung intern im Global Operations Leadership Team verteilt.
- None.
- Loss of key executive (COO) with 12 years of company experience
- Temporary leadership gap in operations with responsibilities being distributed internally
- Organizational uncertainty pending new structure announcement
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Distribution of responsibilities internally
HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019.
Prof. Dr Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: "In his 12-year tenure, Craig has been instrumental in shaping Evotec and Global Operations in particular. On behalf of Evotec's Supervisory Board, I would like to express our sincere gratitude to Craig for his commitment to the Company over the past decade. We wish Craig success in his future endeavours."
Dr Craig Johnstone, Chief Operating Officer of Evotec SE commented: "Thank you to all my talented colleagues across Evotec. Your passion for science and your commitment to excellence are humbling. I wish Evotec long-term success."
Dr Christian Wojczewski, Chief Executive Officer of Evotec, added: "On behalf of the Management Board, I would like to thank Craig for his leadership, passion and dedication to Evotec for the past 12 years. We wish him all the very best for this next chapter."
The responsibilities of the COO function will be distributed internally across the Global Operations Leadership Team until a new organizational structure is designed and announced in line with the Strategic Review.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
When will Dr Craig Johnstone leave his position as COO at Evotec (EVO)?
How long did Dr Craig Johnstone work at Evotec (EVO)?
What will happen to the COO responsibilities at Evotec (EVO) after Johnstone's departure?
